Status	Funding	Financing or Grant by	Project-Name / Acronym	Clinical Centers	Paediatric condition	number of Patients	start-up-meeting	training given or received?
completed	public funding	European Union	**ADDUCE** "Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects"	**(UNIVDUN), UNICA, CIMH, RUNMC, UNIDRE, UMCG**	ADHD, MPH-treated; ADHD non-medication-treated; healthy controls	1600	yes	yes
ongoing	public funding	European Union	**AGGRESSOTYPE** "Aggression subtyping for improved insight and treatment innovation in paediatric psychiatric disorders"	**RUNMC, CIMH, (UNIVDUN), IiSGM/CIBERSAM, UULM, IDIBAPS, UMCG**	Conduct disorder, Oppositionai Defiant Disorder, Aggression		yes	yes
ongoing	public funding	European Union	**MATRICS** - Multidisciplinary Approaches to Translational Research In Conduct Syndromes	**RUNMC, UNICA, CIMH, (UNIVDUN), IiSGM/CIBERSAM, UULM, IDIBAPS, UoM, UMCG**	Conduct disorder, Oppositionai Defiant Disorder, Aggression	300	yes	yes
completed	public funding	European Union	**PERS** "Paediatric European Risperidone Studies"	**RUNMC, UNICA, CIMH, (UNIVDUN), IiSGM/CIBERSAM, UULM, IDIBAPS, UoM, UMCG**	Conduct disorder	400	yes	yes
ongoing	public funding	European Union	**TACTICS** "Translational Adolescent and Childhood Therapeutic Interventions in Compulsive Syndromes"	**RUNMC, CIMH,**	ASD, OCD, ADHD	250	yes	yes
ongoing	public funding	European Union	**EU-AIMS** "European Autism Interventions. A Multicentre Study for Developing New Medications"	**RUNMC, CIMH, UCBM**	ASD	500	yes	yes
completed	public funding	European Union	**STOP** " Suicidality: Treatment Occurring in Pediatric Disorders"	**UNICA, RUNMC„ CIMH, (UNIVDUN), IiSGM/CIBERSAM, UULM, IDIBAPS, UoM, UMCG**	Depression, pats. treated w/o medication, e.g., cognitive behaviour therapy (CBT)	400	yes	yes
ongoing	public funding	European Union	**MILESTONE** : Managing the Link and Strengthening Transition from Child to Adult Mental Health Care	**UULM, UoM**	all conditions except Intellectual deficit	1000	yes	yes
ongoing	public funding	European Union	**EMTICS/** European Multicenter Tics in Children Study	**IDIBAPS, UNIDRE, UMCG**	Tourette syndrome	1200	yes	yes
ongoing	public funding	NIMH USA	**TIC GENETICS/** Collaborative Genomic Studies of Tourette Disorder	**IDIBAPS, UNIDRE, UMCG**	Tourette syndrome	2500	no	no
completed	Industrial	Lilly	**RADAR** ("Randomized Clinical Trial of Atomoxetine in children with Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder symptoms")	**UMCG, RUNMC**	ASD with comorbid ADHD	93	yes	yes
completed	Industrial	Otsuka Pharmaceutical D	**AWARE 31-12-293** (A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents with Tourette's Disorder)	**UNIDRE, UoM, CIMH**	Tics, Tourette's Syndrome (TD)	126	no	yes
completed	Industrial	Otsuka Pharmaceutical D	**AWARE 31-10- 294** (Aripip) in TD	**UNIDRE, UoM, CIMH**	Tics, Tourette's Syndrome (TD)		yes	yes
completed	Industrial	Shire Pharmaceutical De	**SPD503-316** (A Phase 3, Randomised, Double-blind, Multicentre, Parallel-group, Placebo- and Active-reference, Dose-optimisation Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder)	**CIMH, UNIDRE,**	ADHD	250	yes	yes
completed	Industrial	Shire Pharmaceutical Dev	**SPD503-318** (A Phase 3, Open-label, Multicentre, Protocol to Provide Access to Guanfacine Hydrochloride Extended Release for European Subjects with Attention-deficit/Hyperactivity Disorder (ADHD)	**CIMH, UNIDRE**	ADHD	250	yes	yes
completed	Industrial	Shire Pharmaceutical De	**SPD489-325** (LDX) A Phase III, Randomised, double-blind, multicentre, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimisation Safety an Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in children and adolescents aged 6-17 with Attention-Deficit/Hyperactivity Disorder (ADHD)	**(UNIVDUN), UNICA, CIMH, UNIDRE**	ADHD	330	yes	yes
completed	Industrial	Shire Pharmaceutical Dev	**SPD489-326** (LDX) Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17	**(UNIVDUN), UNICA, CIMH, UNIDRE**	ADHD	270	yes	yes
completed	Industrial	Shire Pharmaceutical Dev	**SPD489-404** (A Multicenter, Open-Label Study Evaluating the Safety and Efficacy of Fixed-dose Lisdexamfetamin-Dimesylat in Children and Adolescents aged 6-17 years with Attention-Deficit/Hyperactivity Disorder)	**(UNIVDUN), UNICA, CIMH,**	ADHD	300	yes	yes
completed	Industrial	Shire Pharmaceutical Dev	SPD489-406 (A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE) Compared with OROS-MPH (CONCERTA) witha Placebo Reference Arm, in Adolescents Aged 13-17 Years with Attention-deficit/Hyperactivity Disorder (ADHD)	**(UNIVDUN), UNICA, CIMH,**	ADHD	300	yes	yes
completed	Industrial	Shire Pharmaceutical De	**SPD 489- 317** (LDX)Lisdexamfetamine Dimesylate 2-year Safety Study in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)	**(UNIVDUN), UNICA, CIMH**	ADHD	300	yes	yes
		Lundbeck	**12709A** Interventional, randomised, double-blind, placebo-controlled, active reference (fluoxetine), fixed-dose study of vortioxetine in paediatric patients aged 7 to 12 years, with Major depressive disorder (MDD)"	**UNICA, IiSGM**	Major Depression Disorder		yes	yes
		Lundbeck	**12710A** Interventional, randomised, double-blind, placebo-controlled, active reference (fluoxetine), fixed-dose study of vortioxetine in paediatric patients aged 12 to 17 years, with Major depressive disorder (MDD)"	**UNICA, IiSGM**	Major Depression Disorder	750	yes	yes
		Lundbeck	**127112A** Long-term, open-label, flexible-dose, extension study with vortioxetine in child and adolescent patients with Major Depressive Disorder (MDD) from 7 to 17 years of age	**UNICA, IiSGM**	Major Depression Disorder	250	yes	yes
		Lundbeck	**127112B** Long-term, open-label, flexible-dose, continuation extension study with vortioxetine in child and adolescent patients with Major Depressive Disorder (MDD) from 7 to 17 years of age	**UNICA, IiSGM**	Major Depression Disorder	250	yes	yes

		industrial	Academic			Sub-total		
	ongoing	4	7			11		
	completed	10	3			13		
	Total	14	10			24		